DeFi expert Jim Bianco joins Jared Blikre to break down an interesting year ahead on Wednesday, 1/12 at 2PM ET.
ORLANDO, FL / ACCESSWIRE / January 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband's lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva's FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement is focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA technology.
Nutriband's AVERSA™ abuse deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential. The technology is covered by a broad intellectual property portfolio with a recent notice of allowance from the United States Patent and Trademark Office (USPTO) and international patents granted in Europe, Japan, Korea, Russia, Mexico, and Australia.
Kindeva, a leading global contract development and manufacturing organization (CDMO), has a rich legacy of over 50 years of pharmaceutical innovation as 3M Drug Delivery Systems. Kindeva scientists and engineers include pioneers in the transdermal industry who developed the first drug-in-matrix transdermal patch which has become the standard patch design in the transdermal market. Kindeva currently manufactures millions of branded and generic transdermal patches each year which are distributed globally, primarily in the US, Europe and Asia.
‘We are delighted to partner with Kindeva, a world leader in transdermal product development and manufacturing, to help us bring AVERSA Fentanyl to market. Our focus is to develop our AVERSA abuse deterrent technology to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them,' said Gareth Sheridan, CEO, Nutriband.
‘Kindeva has a long track record of proven innovation in drug delivery, including in transdermal systems. We are excited to bring the talents of our team and our approved product to this feasibility collaboration with Nutriband. Continuing to formulate and develop combination products that are safe and effective for patients is central to our mission,' said Aaron Mann, CEO, Kindeva.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microneedles), and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
SOURCE: Nutriband Inc.
View source version on accesswire.com:
JPMorgan Chase & Co. CEO Jamie Dimon says the consumer remains in great shape in 2022 but also said that volatility could be elevated in financial markets as the Federal Reserve aims to navigate a COVID-induced surge in inflation.
AT&T (NYSE: T) was once considered a stable stock for long-term investors, but it lost more than a third of its value over the past five years. The pandemic exacerbated that pain by disrupting WarnerMedia's theatrical releases and its production of new content. All those headwinds made it tough to invest in AT&T, even as its price-to-earnings ratio dropped to the single digits and its dividend yield hit an all-time high.
Yahoo Finance's Ines Ferre discusses how Tesla stock is rebounding after Goldman Sachs raised their price target for the electric vehicle company.
Shares of GameStop (NYSE: GME) were plummeting 12.7% in morning trading Monday on no news specific to the video game retailer, but it follows the 22% spike in its stock last Friday (it closed up 7% at the end of the day) after it announced it was getting into the non-fungible token (NFT) market in a big way. The markets are reacting to expectations the Federal Reserve will start hiking interest rates as soon as March — meaning there could be as many as four rate hikes this year — as inflation continues to spiral higher. GameStop is looking to build partnerships in the cryptocurrency world and said it would be launching an NFT exchange for gamers by the end of the year.
The stock of QuantumScape (NYSE: QS) crashed 23% in December, according to data provided by S&P Global Market Intelligence. QuantumScape stock is already down another 10.9% this month, as of the time of this writing. The passage of President Joe Biden's $1.2 trillion infrastructure bill that earmarked $7.5 billion on building an EV charging network of 500,000 chargers sent EV stocks surging in November.
Shares of Snowflake (NYSE: SNOW), CrowdStrike Holdings (NASDAQ: CRWD), and MongoDB (NASDAQ: MDB) all fell hard again on Monday, down 8.6%, 7.5%, and 8.3% at their daily lows, respectively, before recovering more than half those losses by 2:10 p.m. ET. There wasn't much in the way of company-specific news today, although MongoDB management did present at the Annual Needham Virtual Growth Conference this morning.
Shares of many stocks in the electric vehicle space opened lower on Monday, amid a broader sell-off of technology stocks on concerns about upcoming inflation data and the beginning of earnings season. Cenntro Electric Group (NASDAQ: NAKD) was down about 10.3%. Nikola (NASDAQ: NKLA) was down about 6.9%.
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are soaring today in response to unaudited sales figures from the fourth quarter and projections for the entire year. The Food and Drug Administration (FDA) approved BioCryst's first drug, Orladeyo, a little over a year ago. The first few quarters post-launch for the drug, which prevents attacks of hereditary angioedema, were less than inspiring.
One thing is certain already: the market environment for 2022 will not be the same as that in 2021. This may or may not be good for investors, per se, but like every shift in market conditions, it will present opportunities for those prepared to grasp them. Some factors are just reruns. COVID is rearing its ugly head again, threatening us with lockdowns and shutdowns. That’s running against the grain of a resurgent economy, an economy that is trying to gain more traction – but it’s facing headwi
Shares of e-commerce software giant Shopify (NYSE: SHOP) were down 6.2% today as of 12:45 p.m. ET. This most recent drop builds on the downturn it and other high-growth stocks have suffered, first from the emergence of the omicron coronavirus variant in late November and now the prospect of higher interest rates from the Federal Reserve to try and tame inflation. Shopify is an incredible company.
The Nasdaq is having a rough morning, but the electric vehicle leader just got several pieces of good news from Wall Street.
Palantir (NYSE: PLTR) stock is losing ground again on Monday. Meanwhile, the S&P 500 index was down roughly 1%, and the even more tech-heavy Nasdaq Composite index was down roughly 1.2% as of 2 p.m. ET. Palantir has gotten hit hard as the market has become more cautious about heavily growth-dependent stocks, and more volatility could be in the cards if risk-heavy investments continue to fall out of favor.
These solid companies are getting unfairly punished by the market. Savvy investors should take note.
Shares of MercadoLibre (NASDAQ: MELI) were down 5.8% as of 12:15 p.m. ET. Latin America's e-commerce and financial technology leader was being dragged down along with other growth stocks following last week's signal from the U.S. Federal Reserve that interest rates might need to be raised faster than originally planned to fight inflation. MercadoLibre is now down some 40% from its last peak in the early autumn of 2021.
ClearBridge Investments, an investment management firm, published its “Dividend Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Dividend Strategy outperformed its S&P 500 Index benchmark during the third quarter. On an absolute basis, the Strategy had gains in six of 11 sectors in which it was […]
iRhythm Technologies, Inc. ( NASDAQ:IRTC ) shareholders might be concerned after seeing the share price drop 13% in the…
After losing nearly one-fifth of its value between March and the end of November last year, Altria (NYSE: MO) began marching higher beginning Dec. 1 and hasn't looked back since. According to data from S&P Global Market Intelligence, the tobacco giant enjoyed a one-month gain of 11.1% in December and is up another 5% so far in 2022. There was no specific company news to account for the run up in Altria's shares, but the tobacco company was trading at a relative discount and it had reported a better-than-expected third-quarter earnings result.
Buckle up stock market bulls, it could be a rough January.
ClearBridge Investments, an investment management firm, published its “Large Cap Growth Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Large Cap Growth Strategy underperformed its Russell 1000 Growth Index benchmark during the third quarter. On an absolute basis, the Strategy had gains across four of the […]
President Trump is planning to return to social media in a big way, but not through the platforms offered by Big Tech. Because they summarily banned him from their sites following the 2020 elections, he is making an end run around them by launching his own platform and will be merging the Trump Media & Technology Group with special purpose acquisition company (SPAC) Digital World Acquisition (NASDAQ: DWAC) to create a publicly traded business. What caught many by surprise was Trump Media's announcement to kick off December that it intended to raise $1 billion by selling shares to hedge funds and other private investors in a PIPE, or private investment in public equity, deal.